A Phase 4 interventional study of Nusinersen in Muscular Atrophy, Spinal, sponsored by Biogen. Completed at 15 sites in 5 countries. Open to participants aged 2 Months to 36 Months. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Biogen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing nusinersen in Muscular Atrophy, Spinal — 3 open to participants now, 4 under way, 2 of them phase 3. nusinersen · Muscular Atrophy, Spinal.
Among the 19 studies testing nusinersen in Muscular Atrophy, Spinal, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 4, and was the 13th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →3 of the 19 studies testing nusinersen in Muscular Atrophy, Spinal are open now, in 8 countries. Recruiting first, the newest first:
Biogen · Sites in United States, France, Germany and 4 more countries
Ages 3+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
By country, each count listing its studies:
nusinersen: first FDA approval 2016 (SPINRAZA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: 2 Months to 36 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 7 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2021.
This study's enrollment of 46 is above the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.
Median enrollment 34 across the 19 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 4 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
27 studies in Muscular Atrophy, Spinal by Biogen: 5 open now, 10 under way, 4 of them phase 3. Of 16 finished, 9 (56%) have results posted.
Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is the 12th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2021, is the only one in phase 4, and was the 15th registered.
Biogen’s Muscular Atrophy, Spinal studies by the year they started, since 2011.
2 of the studies testing nusinersen in Muscular Atrophy, Spinal that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05067790Phase 3BiogenA Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | 2027-09-24 |
| NCT06555419BiogenA Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing nusinersen in Muscular Atrophy, Spinal, from their registry updates:
Among Biogen’s 27 in Muscular Atrophy, Spinal:
This tab as a report to print or save as PDF → With an account.
In this study, researchers will learn more about the use of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on children under the age of 3 who were previously treated with the gene therapy onasemnogene abeparvovec but are still facing health challenges related to their disease.
The main goal of the study is to learn about the effect nusinersen has on muscle and movement ability (motor function). The main question researchers want to answer is:
- What score do participants have on the HINE Section 2 Motor Milestones test after treatment?
The Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones is an assessment that tests movements in different positions. This includes grasping, kicking, head control, rolling, sitting, crawling, standing, and walking.
Researchers will use a group of tests to study body movements, reflexes, balance, and coordination. They will also record if participants need help with breathing.
Researchers will also learn more about the safety of nusinersen. They will check participants for adverse events and changes in vital signs, heart tests, and laboratory tests including blood and urine tests.
The study will be done as follows:
The primary objective of this study is to evaluate the clinical outcomes following treatment with nusinersen in participants with spinal muscular atrophy (SMA) who previously received onasemnogene abeparvovec.
The secondary objectives of this study are to evaluate the safety and tolerability; clinical outcomes and pharmacodynamics (PD) of nusinersen treatment in participants with SMA who previously received onasemnogene abeparvovec.
Key Inclusion Criteria:
For all participants:
Additional Criteria for Subgroups A and B:
Additional Criteria for Subgroup A:
Additional Criteria for Subgroup B:
Key Exclusion Criteria:
For all participants:
Additional Criteria for Subgroups A and B:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Nusinersen 12 milligrams (mg) via intrathecal (IT) injection as loading doses on Days 1, 15, 29, and 64 followed by maintenance doses, every 4 months, on Days 183, 302, 421, 540 and 659.
Drug: Nusinersen
Administered as specified in the treatment arm.
Also known as: ISIS 396443, BIIB058, Spinraza
Total Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones Score
Section 2 of the HINE was used to assess motor milestones of the participants. It is composed of 8 motor milestone categories: voluntary grasp, ability to kick in supine position, head control, rolling, sitting, crawling, standing, and walking. Within each category, 3 to 5 levels can be achieved. Total HINE section 2 motor milestones score was calculated as the sum of each level and can range from 0 to 26. A higher score indicated good neurological function.
Time frame: Up to Day 778
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death; placed the participant at immediate risk of death (according to the investigator's judgment); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a birth defect or was a medically important event.
Time frame: From first dose of study drug up to end of study (up to Day 778)
Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Haematology Parameters)
Hematology parameters included hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, neutrophils, eosinophils, basophils, lymphocytes and monocytes count. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values.
Time frame: Baseline up to Day 778
Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)
Blood chemistry parameters included bilirubin, direct and indirect bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, creatinine, urea nitrogen, cystatin C, sodium, potassium, chloride, bicarbonate, protein, albumin, calcium, phosphate, glucose, and creatine kinase. These parameters were flagged as low, normal, or high relative to the parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline up to Day 778
Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Coagulation Parameters)
Coagulation parameters included activated partial thromboplastin time, prothrombin international (Intl.) normalized ratio and prothrombin time. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline up to Day 778
Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)
Urinalysis included assessments of specific gravity, pH, protein, glucose, ketones, direct bilirubin, occult blood, erythrocytes, leukocytes, epithelial cells, transitional epithelial cells, hyaline casts, ammonium biurate, amorphous crystals, calcium oxalate crystals, triple phosphate crystals and uric acid crystals. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline up to Day 778
Number of Participants With Shift From Baseline in Clinically Significant Abnormalities in Electrocardiograms (ECGs)
Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values postbaseline.
Time frame: Baseline up to Day 778
Number of Participants With Abnormalities in Vital Signs
Vital sign assessment included temperature, heart rate, systolic blood pressure, and diastolic blood pressure. As pre-specified in SAP, the criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \> 38.0 degrees Celsius (C), heart rate increments or decrements of 15 and 30 beats per minute (bpm), systolic blood pressure increments or decrements of 20 and 40 \[millimeters of mercury (mmHg)\], diastolic blood pressure increments or decrements of 10 and 20 mmHg. The categories with at least one participant with clinically relevant vital sign abnormalities are reported.
Time frame: Up to Day 778
Number of Participants Who Achieved Motor Milestones as Assessed by World Health Organization (WHO) Criteria
The WHO motor milestones were a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone and walking alone.
Time frame: Day 778
Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Score
The CHOP-INTEND test was designed to evaluate the motor skills of infants with significant motor weakness. It was evaluated for participants \< 2 years of age at the time of informed consent and for participants 2 to ≤ 3 years of age at the time of informed consent if they did not achieve independent sitting prior to Screening. It included 16 items (capturing neck, trunk, and proximal and distal limb strength), nine of which were scored 0, 1, 2, 3, or 4 with greater scores indicating greater muscle strength, five were scored as 0, 2, or 4, one was scored as 0, 1, 2, or 4, and one as 0, 2, 3, or 4. Total score was calculated as the sum of scores for each item. Total score ranged from 0 (worst possible score) and 64 (best possible score). CHOP-INTEND assessments were discontinued once participants achieved a maximum score of 64 after Day 421, so the number of participants with data points decreased over time.
Time frame: Baseline, Day 778
Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score
The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. It was assessed only in participants aged 2 years and older. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0 = being unable, 1 = performed with some compensation, and 2 = unaided. The overall score is the sum of the scores for all activities and ranged from 0 to 66. Higher scores indicated increased motor function.
Time frame: Baseline, Day 778
Change From Baseline in Revised Upper Limb Module (RULM) Score
RULM test was developed to assess upper limb functional abilities. It was assessed only in participants aged 2 years and older. RULM test: total 19 items. 18 items were assessed on 3-point scale: 0-Unable to achieve independently; 1-Modified method but achieves goal independent of physical assistance from another person; 2-Normal -achieves goal without any assistance. One remaining item was assessed as either 0 or 1. For each item, score was collected on left \& right side. Derived total score=summing scores from these 19 individual items ranging from 0-if participant fails all activities to 37-if participant achieves all activities. If, for an individual item, response was recorded for both left \& right side, highest score was used in calculating total score. Higher scores=increased upper limb function.
Time frame: Baseline, Day 778
Time to Death or Permanent Ventilation
Time to death or permanent ventilation is defined as the time from first dose to death or permanent ventilation (tracheostomy or 16 hours of ventilation/day continuously for \> 21 days in the absence of an acute reversible event), whichever comes first. Time to death or permanent ventilation was estimated using the Kaplan-Meier method.
Time frame: Up to Day 778
Change From (Ratio to) Baseline in Cerebrospinal Fluid (CSF) Levels of Neurofilament Light Subunit (NF-L)
The change from baseline data was reported in terms of geometric mean ratio to baseline. Lower ratios to baseline represent greater reductions in concentrations of NF-L from baseline.
Time frame: Baseline, Day 659
Change From (Ratio to) Baseline in Plasma Levels of NF-L
The change from baseline data was reported in terms of geometric mean ratio to baseline. Lower ratios to baseline represent greater reductions in concentrations of NF-L from baseline.
Time frame: Baseline, Day 778
Participants took part at multiple investigative sites from 04 January 2021 to 09 October 2025.
| Milestone | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Started | 42 | 4 |
| Completed | 35 | 3 |
| Not completed | 7 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Withdrawal by parent and guardian | 5 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Section 2 of the HINE was used to assess motor milestones of the participants. It is composed of 8 motor milestone categories: voluntary grasp, ability to kick in supine position, head control, rolling, sitting, crawling, standing, and walking. Within each category, 3 to 5 levels can be achieved. Total HINE section 2 motor milestones score was calculated as the sum of each level and can range from 0 to 26. A higher score indicated good neurological function.
| score on a scale | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Day 1 | 4.6 ± 4.05 | 15.3 ± 7.89 |
| Day 64 | 7.0 ± 5.18 | 18.00 ± 6.00 |
| Day 183 | 10.1 ± 5.50 | 17.5 ± 6.61 |
| Day 302 | 12.8 ± 5.25 | 18.3 ± 5.13 |
| Day 421 | 13.6 ± 5.32 | 20.0 ± 5.29 |
| Day 540 | 14.5 ± 6.08 | 22.0 ± 4.00 |
| Day 659 | 16.4 ± 5.65 | 21.3 ± 4.16 |
| Day 778 | 17.0 ± 5.68 | 21.7 ± 2.89 |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death; placed the participant at immediate risk of death (according to the investigator's judgment); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a birth defect or was a medically important event.
| Participants | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| AEs | 39 | 4 |
| SAEs | 24 | 2 |
Hematology parameters included hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, neutrophils, eosinophils, basophils, lymphocytes and monocytes count. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values.
| Participants | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Hemoglobin: Shift to Low | 4 | 0 |
| Hemoglobin: Shift to High | 2 | 0 |
| Hematocrit: Shift to Low | 1 | 0 |
| Hematocrit: Shift to High | 7 | 0 |
| Erythrocytes: Shift to Low | 0 | 0 |
| Erythrocytes: Shift to High | 4 | 0 |
| Leukocytes: Shift to Low | 6 | 0 |
| Leukocytes: Shift to High | 17 | 2 |
| Neutrophils: Shift to Low | 12 | 1 |
| Neutrophils: Shift to High | 8 | 2 |
| Neutrophils/Leukocytes: Shift to Low | 22 | 0 |
| Neutrophils/Leukocytes: Shift to High | 1 | 1 |
| Eosinophils/Leukocytes: Shift to Low | 0 | 0 |
| Eosinophils/Leukocytes: Shift to High | 16 | 3 |
| Basophils/Leukocytes: Shift to Low | 0 | 0 |
| Basophils/Leukocytes: Shift to High | 18 | 3 |
| Lymphocytes/Leukocytes: Shift to Low | 1 | 1 |
| Lymphocytes/Leukocytes: Shift to High | 19 | 0 |
| Monocytes/Leukocytes: Shift to Low | 17 | 2 |
| Monocytes/Leukocytes: Shift to High | 5 | 0 |
| Basophils: Shift to Low | 0 | 0 |
| Basophils: Shift to High | 16 | 3 |
| Lymphocytes: Shift to Low | 0 | 0 |
| Lymphocytes: Shift to High | 23 | 1 |
| Monocytes: Shift to Low | 6 | 0 |
| Monocytes: Shift to High | 11 | 1 |
| Eosinophils: Shift to Low | 1 | 0 |
| Eosinophils: Shift to High | 13 | 2 |
| Platelets: Shift to Low | 1 | 0 |
| Platelets: Shift to High | 11 | 0 |
Blood chemistry parameters included bilirubin, direct and indirect bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, creatinine, urea nitrogen, cystatin C, sodium, potassium, chloride, bicarbonate, protein, albumin, calcium, phosphate, glucose, and creatine kinase. These parameters were flagged as low, normal, or high relative to the parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Bilirubin: Shift to Low | 1 | 0 |
| Bilirubin: Shift to High | 0 | 0 |
| Indirect Bilirubin: Shift to Low | 29 | 2 |
| Indirect Bilirubin: Shift to High | 0 | 0 |
| Alkaline Phosphatase: Shift to Low | 0 | 0 |
| Alkaline Phosphatase: Shift to High | 7 | 1 |
| Alanine Aminotransferase: Shift to Low | 0 | 0 |
| Alanine Aminotransferase: Shift to High | 12 | 0 |
| Aspartate Aminotransferase: Shift to Low | 0 | 0 |
| Aspartate Aminotransferase: Shift to High | 4 | 0 |
| Gamma Glutamyl Transferase: Shift to Low | 2 | 0 |
| Gamma Glutamyl Transferase: Shift to High | 0 | 0 |
| Urea Nitrogen: Shift to Low | 2 | 0 |
| Urea Nitrogen: Shift to High | 5 | 1 |
| Cystatin C: Shift to Low | 3 | 0 |
| Cystatin C: Shift to High | 0 | 0 |
| Sodium: Shift to Low | 0 | 1 |
| Sodium: Shift to High | 0 | 0 |
| Potassium: Shift to Low | 0 | 0 |
| Potassium: Shift to High | 11 | 1 |
| Chloride: Shift to Low | 0 | 0 |
| Chloride: Shift to High | 0 | 1 |
| Bicarbonate: Shift to Low | 9 | 2 |
| Bicarbonate: Shift to High | 1 | 0 |
| Protein: Shift to Low | 1 | 0 |
| Protein: Shift to High | 8 | 0 |
| Calcium: Shift to Low | 2 | 1 |
| Calcium: Shift to High | 12 | 0 |
| Phosphate: Shift to Low | 0 | 0 |
| Phosphate: Shift to High | 16 | 2 |
| Glucose: Shift to Low | 5 | 1 |
| Glucose: Shift to High | 17 | 0 |
| Creatine Kinase: Shift to Low | 0 | 0 |
| Creatine Kinase: Shift to High | 8 | 0 |
Coagulation parameters included activated partial thromboplastin time, prothrombin international (Intl.) normalized ratio and prothrombin time. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Activated Partial Thromboplastin Time: Shift to Low | 5 | 0 |
| Activated Partial Thromboplastin Time: Shift to High | 3 | 1 |
| Prothrombin Intl. Normalized Ratio: Shift to Low | 0 | 0 |
| Prothrombin Intl. Normalized Ratio: Shift to High | 3 | 1 |
| Prothrombin Time: Shift to Low | 2 | 0 |
| Prothrombin Time: Shift to High | 5 | 1 |
Urinalysis included assessments of specific gravity, pH, protein, glucose, ketones, direct bilirubin, occult blood, erythrocytes, leukocytes, epithelial cells, transitional epithelial cells, hyaline casts, ammonium biurate, amorphous crystals, calcium oxalate crystals, triple phosphate crystals and uric acid crystals. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Specific Gravity: Shift to Low | 0 | 0 |
| Specific Gravity: Shift to High | 3 | 0 |
| pH: Shift to Low | 0 | 0 |
| pH: Shift to High | 17 | 1 |
| Protein All: (High/Positive (Pos) | 29 | 3 |
| Glucose: High/Pos | 1 | 0 |
| Ketones: High/Pos | 20 | 0 |
| Direct Bilirubin: High/Pos | 1 | 0 |
| Occult Blood: High/Pos | 7 | 0 |
| Erythrocytes (/high power field [HPF]): High/Pos | 24 | 2 |
| Leukocytes (/HPF): High/Pos | 23 | 2 |
| Epithelial Cells: High/Pos | 3 | 0 |
| Transitional Epithelial Cells: High/Pos | 5 | 0 |
| Ammonium Biurate Crystals: High/Pos | 1 | 0 |
| Amorphous Crystals: High/Pos | 21 | 0 |
| Calcium Oxalate Crystals: High/Pos | 12 | 1 |
| Triple Phosphate Crystals: High/Pos | 2 | 0 |
| Uric Acid Crystals: High/Pos | 5 | 1 |
Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values postbaseline.
| Participants | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Shift to abnormal, not adverse event | 16 | 1 |
| Shift to abnormal, adverse event | 0 | 0 |
Vital sign assessment included temperature, heart rate, systolic blood pressure, and diastolic blood pressure. As pre-specified in SAP, the criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \> 38.0 degrees Celsius (C), heart rate increments or decrements of 15 and 30 beats per minute (bpm), systolic blood pressure increments or decrements of 20 and 40 \[millimeters of mercury (mmHg)\], diastolic blood pressure increments or decrements of 10 and 20 mmHg. The categories with at least one participant with clinically relevant vital sign abnormalities are reported.
| Participants | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Temperature >38 degrees C | 0 | 0 |
| Heart rate Increment or decrement of 15 bpm | 42 | 3 |
| Heart rate Increment or decrement of 30 bpm | 34 | 3 |
| Systolic blood pressure Increment or decrement of 20 mmHg | 37 | 3 |
| Systolic blood pressure Increment or decrement of 40 mmHg | 11 | 0 |
| Diastolic blood pressure Increment or decrement of 10 mmHg | 41 | 4 |
| Diastolic blood pressure Increment or decrement of 20 mmHg | 30 | 3 |
The WHO motor milestones were a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone and walking alone.
| Participants | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Sitting without support — 1 - No Ability | 4 | 0 |
| Sitting without support — 2- No (Refusal) | 0 | 0 |
| Sitting without support — 3 - Yes | 32 | 3 |
| Sitting without support — 9 - Unable to test | 0 | 0 |
| Hands-and-Knees Crawling — 1 - No Ability | 31 | 1 |
| Hands-and-Knees Crawling — 2- No (Refusal) | 0 | 0 |
| Hands-and-Knees Crawling — 3 - Yes | 5 | 2 |
| Hands-and-Knees Crawling — 9 - Unable to test | 0 | 0 |
| Standing With Assistance — 1 - No Ability | 23 | 2 |
| Standing With Assistance — 2- No (Refusal) | 0 | 0 |
| Standing With Assistance — 3 - Yes | 13 | 1 |
| Standing With Assistance — 9 - Unable to test | 0 | 0 |
| Walking With Assistance — 1 - No Ability | 28 | 2 |
| Walking With Assistance — 2- No (Refusal) | 0 | 0 |
| Walking With Assistance — 3 - Yes | 8 | 1 |
| Walking With Assistance — 9 - Unable to test | 0 | 0 |
| Standing Alone — 1 - No Ability | 32 | 2 |
| Standing Alone — 2- No (Refusal) | 0 | 0 |
| Standing Alone — 3 - Yes | 4 | 1 |
| Standing Alone — 9 - Unable to test | 0 | 0 |
| Walking Alone — 1 - No Ability | 33 | 2 |
| Walking Alone — 2- No (Refusal) | 0 | 0 |
| Walking Alone — 3 - Yes | 3 | 1 |
| Walking Alone — 9 - Unable to test | 0 | 0 |
The CHOP-INTEND test was designed to evaluate the motor skills of infants with significant motor weakness. It was evaluated for participants \< 2 years of age at the time of informed consent and for participants 2 to ≤ 3 years of age at the time of informed consent if they did not achieve independent sitting prior to Screening. It included 16 items (capturing neck, trunk, and proximal and distal limb strength), nine of which were scored 0, 1, 2, 3, or 4 with greater scores indicating greater muscle strength, five were scored as 0, 2, or 4, one was scored as 0, 1, 2, or 4, and one as 0, 2, 3, or 4. Total score was calculated as the sum of scores for each item. Total score ranged from 0 (worst possible score) and 64 (best possible score). CHOP-INTEND assessments were discontinued once participants achieved a maximum score of 64 after Day 421, so the number of participants with data points decreased over time.
| score on a scale | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Score | 14.7 ± 8.18 | — |
The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. It was assessed only in participants aged 2 years and older. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0 = being unable, 1 = performed with some compensation, and 2 = unaided. The overall score is the sum of the scores for all activities and ranged from 0 to 66. Higher scores indicated increased motor function.
| score on a scale | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score | 7.0 ± 1.41 | 9.7 ± 2.08 |
RULM test was developed to assess upper limb functional abilities. It was assessed only in participants aged 2 years and older. RULM test: total 19 items. 18 items were assessed on 3-point scale: 0-Unable to achieve independently; 1-Modified method but achieves goal independent of physical assistance from another person; 2-Normal -achieves goal without any assistance. One remaining item was assessed as either 0 or 1. For each item, score was collected on left \& right side. Derived total score=summing scores from these 19 individual items ranging from 0-if participant fails all activities to 37-if participant achieves all activities. If, for an individual item, response was recorded for both left \& right side, highest score was used in calculating total score. Higher scores=increased upper limb function.
| score on a scale | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Change From Baseline in Revised Upper Limb Module (RULM) Score | 13.0 ± NA | 8.0 ± 3.61 |
Time to death or permanent ventilation is defined as the time from first dose to death or permanent ventilation (tracheostomy or 16 hours of ventilation/day continuously for \> 21 days in the absence of an acute reversible event), whichever comes first. Time to death or permanent ventilation was estimated using the Kaplan-Meier method.
| days | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Time to Death or Permanent Ventilation | NA (NA to NA) | NA (NA to NA) |
The change from baseline data was reported in terms of geometric mean ratio to baseline. Lower ratios to baseline represent greater reductions in concentrations of NF-L from baseline.
| ratio | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Change From (Ratio to) Baseline in Cerebrospinal Fluid (CSF) Levels of Neurofilament Light Subunit (NF-L) | 0.13 (0.10 to 0.16) | 0.34 (0.01 to 10.79) |
The change from baseline data was reported in terms of geometric mean ratio to baseline. Lower ratios to baseline represent greater reductions in concentrations of NF-L from baseline.
| ratio | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Change From (Ratio to) Baseline in Plasma Levels of NF-L | 0.13 (0.10 to 0.17) | 0.29 (0.03 to 2.74) |
Collected over From first dose of study drug up to end of study (up to Day 778). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nusinersen 2 SMN2 Copies | 1/42 (2.4%) | 24/42 (57.1%) | 38/42 (90.5%) |
| Nusinersen 3 SMN2 Copies | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Event | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Pneumonia moraxellaInfections and infestations | 0/42 | 1/4 |
| Rhinovirus infectionInfections and infestations | 3/42 | 1/4 |
| Tendinous contractureMusculoskeletal and connective tissue disorders | 0/42 | 1/4 |
| PneumoniaInfections and infestations | 8/42 | 0/4 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 5/42 | 0/4 |
| Parainfluenzae virus infectionInfections and infestations | 3/42 | 0/4 |
| DehydrationMetabolism and nutrition disorders | 3/42 | 0/4 |
| Developmental hip dysplasiaCongenital, familial and genetic disorders | 2/42 | 0/4 |
| Metapneumovirus pneumoniaInfections and infestations | 2/42 | 0/4 |
| Pneumonia viralInfections and infestations | 2/42 | 0/4 |
| Event | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 14/42 | 1/4 |
| PyrexiaGeneral disorders | 13/42 | 0/4 |
| EosinophiliaBlood and lymphatic system disorders | 0/42 | 1/4 |
| Ear painEar and labyrinth disorders | 1/42 | 1/4 |
| Middle ear effusionEar and labyrinth disorders | 0/42 | 1/4 |
| VomitingGastrointestinal disorders | 8/42 | 1/4 |
| InfluenzaInfections and infestations | 5/42 | 1/4 |
| NasopharyngitisInfections and infestations | 7/42 | 1/4 |
| RhinitisInfections and infestations | 2/42 | 1/4 |
| Viral upper respiratory tract infectionInfections and infestations | 6/42 | 1/4 |
The Intent-to-Treat (ITT) set included all participants who received at least 1 dose of nusinersen in the study.
| Age, Continuous(months) | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies | Total |
|---|---|---|---|
| Mean | 10.61 ± 6.090 | 32.79 ± 3.255 | 12.54 ± 8.627 |
| Sex: Female, Male(Participants) | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies | Total |
|---|---|---|---|
| Female | 16 | 1 | 17 |
| Male | 26 | 3 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 4 |
| Not Hispanic or Latino | 38 | 4 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Nusinersen 2 SMN2 Copies | Nusinersen 3 SMN2 Copies | Total |
|---|---|---|---|
| Race — American Indian or Alaska native | 0 | 0 | 0 |
| Race — Asian | 0 | 1 | 1 |
| Race — Black or African American | 3 | 1 | 4 |
| Race — Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Race — White | 36 | 2 | 38 |
| Race — Multiple | 1 | 0 | 1 |
| Race — Not reported due to confidentiality regulations | 0 | 0 | 0 |
| Race — Other | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/
Data sharing details ↗ · vivli.org
Ran from Jan 2021 to primary completion in Oct 2025, 57 months.
Results were first posted in Oct 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nusinersen